Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, talks about this new adenovirus vector-based gene therapy, how it works, how it's administered, and who would benefit from this latest treatment options for non-muscle invasive bladder cancer (NMIBC).
Contents of this video:
00:00 Intro
04:49 Defining the BCG Unresponsive Population
07:06 What is Gene Therapy
14:32 Adenoviral Gene Therapy
21:40 Concerns Over the Safety of Gene Therapy
28:15 The Future of Adstiladrin
